Comments on: Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to

Comments on: Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis https://9krapalm.com/akesos-ebdarokimab-il-12-il-23-dual-targeted-monoclonal-antibody-approved-in-china-for-moderate-to-severe-plaque-psoriasis/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Fri, 18 Apr 2025 12:50:18 +0000 hourly 1 https://wordpress.org/?v=7.0